Imara reports FY2021 net loss $51.4M; interim Phase 2b data expected April 2022

Enliven Therapeutics, Inc.

Net loss $51.4M ($2.37 per share) vs $49.2M ($3.53 per share) in FY2020; cash $90.3M at Dec 31, 2021.
Phase 2b SCD and beta-thalassemia trials fully enrolled; interim data from both trials expected first week of April 2022.
FDA required change of Ardent SCD trial primary endpoint to annualized VOC rate; conduct unchanged.
Added HFpEF indication for tovinontrine; Phase 2 trial dosing expected Q2 2022; pipeline expanded with IMR-261.
FY2022 guidance: R&D $60-65M, G&A $13-15M; cash runway through Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.